Related Experiment Video

Updated: Oct 8, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K

Role of High-Density Lipoprotein Cholesterol (HDL-C) as a Clinical Predictor of Decompensation in Patients with

Harshavardhan Rao B1, Priya Nair1, Anoop K Koshy1

  • 1Department of Gastroenterology, Amrita Institute of Medical Sciences, Kochi, Kerala 682041, India.

International Journal of Hepatology
|January 3, 2022
PubMed

Insights

Low high-density lipoprotein cholesterol (HDL-C) levels predict decompensation in chronic liver disease (CLD) patients. Measuring HDL-C can help identify patients at higher risk for liver decompensation, aiding treatment decisions.

Area of Science:

  • Hepatology
  • Cardiovascular Medicine
  • Immunology

Background:

  • Systemic inflammation from bacterial products like lipopolysaccharides (LPS) contributes to chronic liver disease (CLD) decompensation.
  • High-density lipoprotein cholesterol (HDL-C) plays a role in the innate immune response to LPS.
  • This study investigates HDL-C as a prognostic marker for decompensation in CLD patients.

Purpose of the Study:

  • To explore the role of HDL-C as a prognostic marker for decompensation in patients with chronic liver disease.
  • To determine if HDL-C levels can predict the risk of decompensation events in CLD.

Main Methods:

  • Prospective, observational cohort study design.
  • Inclusion of consecutive patients with CLD, excluding cholestatic liver disease and hepatocellular carcinoma.
  • Measurement of fasting lipids and follow-up for decompensation events (ascites, hepatic encephalopathy, variceal bleed).

Main Results:

  • 170 CLD patients included; 57% experienced decompensation.
  • Mean HDL-C was significantly lower in patients with decompensation (27.5 mg/dL) compared to those without (43.5 mg/dL).
  • An HDL-C cutoff of 36.4 mg/dL predicted decompensation risk, with lower levels independently associated (OR = 6.072).

Conclusions:

  • HDL-C levels below 36.4 mg/dL are a reliable risk marker for decompensation in CLD.
  • HDL-C can enhance existing prognostic scoring systems for CLD.
  • This marker can aid in streamlining treatment and prioritizing liver transplantation.
Abstract

More Related Videos

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

7.6K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
732
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
14
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
13
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
330
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
938
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
295